Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.5K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

809
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
809
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Blood advances·2026
Same author

Neurogenic Lower Urinary Tract Dysfunction in Women With Multiple Sclerosis.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Rapid HHV-6 Clearance Following Preemptive Short-Course Foscarnet in Allogeneic Stem Cell Transplant Recipients.

American journal of hematology·2026
Same author

Impact of Stem Cell Mobilization with Chemotherapy Versus G-CSF Alone for Multiple Myeloma Patients with Suboptimal Response Before Autologous Stem Cell Transplant.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Efficacy of CD19 CAR T-cell therapy for patients with B-cell acute lymphoblastic leukemia relapsed after allogeneic transplantation.

Leukemia & lymphoma·2026
Same author

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Jan 7, 2026

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

21.1K

Autologous Stem Cell Transplantation for Multiple Sclerosis.

Shreya Condamoor1, Pongthep Vittayawacharin1, Michael Sy2

  • 1Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, The University of California Irvine, Orange, California.

Transplantation and Cellular Therapy
|January 2, 2026
PubMed
Summary
This summary is machine-generated.

Autologous hematopoietic stem cell transplantation (AHSCT) offers sustained remission and prevents further debilitation in many relapsing-remitting multiple sclerosis (MS) patients resistant to disease-modifying therapies (DMTs). While outcomes vary in progressive MS, AHSCT shows promise for higher no evidence of disease activity rates and slower disease progression.

Keywords:
Autologous hematopoietic stem cell transplantationBEAM regimenConditioning regimenEpstein–Barr virusMolecular mimicryMultiple sclerosis

More Related Videos

Surgical Transplantation of Mouse Neural Stem Cells into the Spinal Cords of Mice Infected with Neurotropic Mouse Hepatitis Virus
08:33

Surgical Transplantation of Mouse Neural Stem Cells into the Spinal Cords of Mice Infected with Neurotropic Mouse Hepatitis Virus

Published on: July 10, 2011

23.8K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

854

Related Experiment Videos

Last Updated: Jan 7, 2026

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

21.1K
Surgical Transplantation of Mouse Neural Stem Cells into the Spinal Cords of Mice Infected with Neurotropic Mouse Hepatitis Virus
08:33

Surgical Transplantation of Mouse Neural Stem Cells into the Spinal Cords of Mice Infected with Neurotropic Mouse Hepatitis Virus

Published on: July 10, 2011

23.8K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

854

Area of Science:

  • Neuroimmunology
  • Stem Cell Transplantation
  • Autoimmune Disorders

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, and neurodegenerative disease of the central nervous system.
  • Current disease-modifying therapies (DMTs) are the standard of care but are often insufficient for patients with persistent disease activity.
  • Autologous hematopoietic stem cell transplantation (AHSCT) is an alternative for treatment-resistant cases.

Purpose of the Study:

  • To review the current evidence on the efficacy and outcomes of AHSCT in treating multiple sclerosis.
  • To focus on optimal timing, transplant outcomes, and conditioning regimens for AHSCT.
  • To compare AHSCT outcomes with existing DMTs and explore future therapeutic comparisons.

Main Methods:

  • Systematic review of existing studies and clinical data on AHSCT for MS.
  • Analysis of patient outcomes, including remission rates, disease activity, and neurological status.
  • Evaluation of conditioning regimens and treatment-related mortality associated with AHSCT.

Main Results:

  • AHSCT demonstrates high rates of sustained remission and no evidence of disease activity (NEDA) in DMT-resistant relapsing-remitting MS (RRMS).
  • AHSCT can prevent further debilitation and improve neurological outcomes in RRMS patients.
  • AHSCT shows potential for slowing disease progression in progressive MS, with very low treatment-related mortality.
  • AHSCT generally achieves higher NEDA rates and lower relapse rates compared to DMTs.

Conclusions:

  • AHSCT is a highly effective therapeutic option for DMT-resistant RRMS, offering sustained remission and improved outcomes.
  • Further research is required to optimize patient selection and conditioning regimens for AHSCT in MS.
  • Comparative studies with emerging therapies like CAR T-cell therapy are needed to define the future role of AHSCT.